{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:17:50Z","timestamp":1791343070329,"version":"4.3.1"},"reference-count":212,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,10,3]],"date-time":"2007-10-03T00:00:00Z","timestamp":1191369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2007,11]]},"abstract":"<jats:p>From time to time we publish a full review of drugs that are available for the treatment of common conditions. In this issue, the review is written by two of the leading authorities in the world, Paul Abrams and Karl\u2010Erik Andersson, on the topic of overactive bladder and antimuscarinic agents. This in\u2010depth review covers the entire range of questions that might be asked about this common area of interest.<\/jats:p>\n                  <jats:p>\n                    Overactive bladder (OAB) is a syndrome characterized by urinary urgency, with or without urgency urinary incontinence, usually with frequency and nocturia. OAB symptoms are often associated with detrusor overactivity (DO). Like OAB symptoms, the prevalence of DO increases with age and can have a neurogenic and\/or myogenic aetiology. Bladder outlet obstruction can be a contributing factor in DO, possibly through cholinergic denervation of the detrusor and supersensitivity of muscarinic receptors to acetylcholine, although the prevalence of OAB is similar in men and women across age groups. Acetylcholine is the primary contractile neurotransmitter in the human detrusor, and antimuscarinics exert their effects on OAB\/DO by inhibiting the binding of acetylcholine at muscarinic receptors M\n                    <jats:sub>2<\/jats:sub>\n                    and M\n                    <jats:sub>3<\/jats:sub>\n                    on detrusor smooth muscle cells and other structures within the bladder wall. Worldwide, there are six antimuscarinic drugs currently marketed for the treatment of OAB: oxybutynin, tolterodine, propiverine, trospium, darifenacin, and solifenacin. Each has demonstrated efficacy for the treatment of OAB symptoms, but their pharmacokinetic and adverse event profiles differ somewhat due to structural differences (tertiary vs quaternary amines), muscarinic receptor subtype selectivities, and organ selectivities. Antimuscarinics are generally well tolerated, even in special populations (e.g. men with bladder outlet obstruction, elderly patients, children). The most frequently reported adverse events in clinical studies of antimuscarinics are dry mouth, constipation, headache, and blurred vision; few patients withdraw from clinical trials because of adverse events.\n                  <\/jats:p>\n                  <jats:p>\n                    Development of an antimuscarinic with functional selectivity for the bladder would reduce the occurrence of antimuscarinic adverse events. The therapeutic potential of several other agents, such as \u03b1\n                    <jats:sub>3<\/jats:sub>\n                    \u2010adrenoceptor agonists, purinergic receptor antagonists, phosphodiesterase inhibitors, neurokinin\u20101 receptor antagonists, opioids, and Rho\u2010kinase inhibitors, is also under investigation for the treatment of OAB.\n                  <\/jats:p>","DOI":"10.1111\/j.1464-410x.2007.07205.x","type":"journal-article","created":{"date-parts":[[2010,8,9]],"date-time":"2010-08-09T20:56:32Z","timestamp":1281387392000},"page":"987-1006","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":339,"title":["Muscarinic receptor antagonists for overactive bladder"],"prefix":"10.1111","volume":"100","author":[{"given":"Paul","family":"Abrams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl\u2010Erik","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,10,3]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)02243-4"},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.09.019"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2004.74008.x"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2003.04527.x"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)00986-4"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01803-4"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(98)00581-5"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.56.4.4"},{"key":"e_1_2_10_12_2","first-page":"811","volume-title":"3rd International Consultation on Incontinence.","author":"Morrison J","year":"2005"},{"key":"e_1_2_10_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706604"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01786-7"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.1930090108"},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9861(19990111)403:2<209::AID-CNE5>3.0.CO;2-X"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01633-8"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(24)29617-8"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64367-4"},{"key":"e_1_2_10_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)00004-2"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)65982-4"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10099"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464150-00003"},{"issue":"4","key":"e_1_2_10_24_2","first-page":"S7","article-title":"Pathophysiology of overactive bladder and urge urinary incontinence","volume":"4","author":"Steers WD","year":"2002","journal-title":"Rev Urol"},{"key":"e_1_2_10_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1474-8673.2006.00363.x"},{"key":"e_1_2_10_26_2","first-page":"227","volume-title":"Nervous Control of the Urogenital System","author":"De Groat WC","year":"1993"},{"key":"e_1_2_10_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2003.11.003"},{"key":"e_1_2_10_28_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0302-2838(02)00540-7","article-title":"Antimuscarinics and the overactive detrusor \u2013 which is the main mechanism of action?","volume":"43","author":"Andersson KE","year":"2003","journal-title":"Eur Urol"},{"key":"e_1_2_10_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.1930120504"},{"key":"e_1_2_10_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.1930040403"},{"key":"e_1_2_10_31_2","doi-asserted-by":"publisher","DOI":"10.1113\/eph8802473"},{"key":"e_1_2_10_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2003.04667.x"},{"key":"e_1_2_10_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05455.x"},{"key":"e_1_2_10_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1474-8673.2006.00364.x"},{"key":"e_1_2_10_35_2","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2005.097311"},{"key":"e_1_2_10_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00591-8"},{"key":"e_1_2_10_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)35868-8"},{"key":"e_1_2_10_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1987.tb05033.x"},{"key":"e_1_2_10_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01788-0"},{"key":"e_1_2_10_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.57.2.169"},{"key":"e_1_2_10_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64291-7"},{"key":"e_1_2_10_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01544-3"},{"key":"e_1_2_10_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-6997(24)01362-0"},{"key":"e_1_2_10_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01819-8"},{"key":"e_1_2_10_45_2","doi-asserted-by":"publisher","DOI":"10.2165\/00066982-200408010-00003"},{"key":"e_1_2_10_46_2","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0022-3565(25)09628-4","article-title":"Muscarinic acetylcholine receptor subytpes mediating urinary bladder contractility and coupling to GTP binding proteins","volume":"273","author":"Wang P","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_10_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65752-5"},{"key":"e_1_2_10_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(06)00563-5"},{"key":"e_1_2_10_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-6997(25)06957-1"},{"key":"e_1_2_10_50_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1474-8673.2002.00258.x"},{"key":"e_1_2_10_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1474-8673.2006.00368.x"},{"key":"e_1_2_10_52_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.17.9579"},{"key":"e_1_2_10_53_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000138054.77785.4a"},{"key":"e_1_2_10_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)68997-5"},{"key":"e_1_2_10_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)38030-8"},{"key":"e_1_2_10_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)67039-3"},{"key":"e_1_2_10_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704241"},{"key":"e_1_2_10_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705109"},{"key":"e_1_2_10_59_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.063735"},{"key":"e_1_2_10_60_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.094961"},{"key":"e_1_2_10_61_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000130419.32165.6b"},{"key":"e_1_2_10_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701048"},{"key":"e_1_2_10_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(98)00583-9"},{"key":"e_1_2_10_64_2","doi-asserted-by":"crossref","first-page":"C1723","DOI":"10.1152\/ajpcell.1993.265.6.C1723","article-title":"Muscarinic inhibition of ATP\u2010sensitive K+ channels by protein kinase C in urinary bladder smooth muscle","volume":"265","author":"Bonev AD","year":"1993","journal-title":"Am J Physiol"},{"key":"e_1_2_10_65_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-2042.2002.00548.x"},{"key":"e_1_2_10_66_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.077909"},{"key":"e_1_2_10_67_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.1998.275.5.R1654"},{"key":"e_1_2_10_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(98)00582-7"},{"key":"e_1_2_10_69_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00116.2002"},{"key":"e_1_2_10_70_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.097303"},{"key":"e_1_2_10_71_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mou.0000172393.52857.92"},{"key":"e_1_2_10_72_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00009.2003"},{"key":"e_1_2_10_73_2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0022-5347(18)37789-9","article-title":"Muscarinic receptor function in the idiopathic overactive bladder","volume":"171","author":"Stevens L","year":"2004","journal-title":"J Urol"},{"key":"e_1_2_10_74_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0022-5347(18)37797-8","article-title":"A comparison of muscarinic receptor\u2010mediated function in the normal and the neurogenic overactive bladder","volume":"171","author":"Stevens L","year":"2004","journal-title":"J Urol"},{"key":"e_1_2_10_75_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00391.2003"},{"key":"e_1_2_10_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00221-6"},{"key":"e_1_2_10_77_2","doi-asserted-by":"publisher","DOI":"10.1159\/000030309"},{"key":"e_1_2_10_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1838(92)90237-B"},{"key":"e_1_2_10_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)10643-5"},{"key":"e_1_2_10_80_2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0022-3565(24)37044-2","article-title":"M4 muscarinic autoreceptor\u2010mediated inhibition of 3H\u2010acetylcholine release in the rat isolated urinary bladder","volume":"283","author":"D\u2019Agostino G","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_10_81_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703080"},{"key":"e_1_2_10_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(98)00580-3"},{"key":"e_1_2_10_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-0186(02)00193-6"},{"key":"e_1_2_10_84_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706147"},{"key":"e_1_2_10_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)61988-8"},{"key":"e_1_2_10_86_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703068"},{"key":"e_1_2_10_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2003.09.030"},{"key":"e_1_2_10_88_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000176793.50410.9e"},{"key":"e_1_2_10_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.03.006"},{"key":"e_1_2_10_90_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20208"},{"key":"e_1_2_10_91_2","doi-asserted-by":"crossref","unstructured":"IijimaK De WachterS WyndaeleJJ. Effects of the M3receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve.Eur Urol2007[Epub ahead of print]","DOI":"10.1016\/j.eururo.2007.02.057"},{"key":"e_1_2_10_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(06)60810-5"},{"key":"e_1_2_10_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00622-7"},{"key":"e_1_2_10_94_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003081-199006000-00021"},{"key":"e_1_2_10_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)90009-7"},{"key":"e_1_2_10_96_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2004.00234.x"},{"key":"e_1_2_10_97_2","doi-asserted-by":"publisher","DOI":"10.1191\/0962280204sm357ra"},{"key":"e_1_2_10_98_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001703-200110000-00012"},{"key":"e_1_2_10_99_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.10.009"},{"key":"e_1_2_10_100_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016370925601"},{"key":"e_1_2_10_101_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20110"},{"key":"e_1_2_10_102_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1023422208910"},{"key":"e_1_2_10_103_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7394.841"},{"key":"e_1_2_10_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.02.024"},{"key":"e_1_2_10_105_2","first-page":"102","article-title":"[The elderly patient with urge incontinence or urge\u2010stress incontinence \u2013 efficacy and cardiac safety of propiverine]","volume":"34","author":"Dorschner W","year":"2003","journal-title":"Aktuelle Urol"},{"key":"e_1_2_10_106_2","unstructured":"J\u00fcnemannKP HessdoerferE Unamba\u2010OparahIet\u2003al.Propiverine hydrochloride immediate (IR) and extended release (ER): comparison of efficacy and tolerability in patients with overactive bladder.International Continence Society 34th Annual Meeting; 2004; Paris France.2004 Abstract143"},{"key":"e_1_2_10_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.05.043"},{"key":"e_1_2_10_108_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05454.x"},{"key":"e_1_2_10_109_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X178801"},{"key":"e_1_2_10_110_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.01.008"},{"key":"e_1_2_10_111_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2006.06035.x"},{"key":"e_1_2_10_112_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000103540.71683.e5"},{"key":"e_1_2_10_113_2","unstructured":"Sanctura\u00ae (Trospium chloride).Full Prescribing Information. Odyssey Pharmaceuticals Inc. Indevus. Pharmaceuticals Inc. Lexington MA and East Hanover NJ USA;2004"},{"key":"e_1_2_10_114_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-003-0023-1"},{"key":"e_1_2_10_115_2","unstructured":"Ditropan\u00ae XL (oxybutynin chloride).Full Prescribing Information. Ortho\u2010McNeil Pharmaceutical Inc. Raritan NJ USA;2004"},{"key":"e_1_2_10_116_2","unstructured":"Detrol\u00ae (tolterodine tartrate).Full Prescribing Information. Pharmacia & Upjohn Company Kalamazoo MI USA;2003"},{"key":"e_1_2_10_117_2","unstructured":"VESIcare\u00ae (Solifenacin succinate).Full Prescribing Information. Yamanouchi Pharma America Inc. and GlaxoSmithKline Norman OK USA;2004"},{"key":"e_1_2_10_118_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200320110-00007"},{"key":"e_1_2_10_119_2","first-page":"40","article-title":"Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies","volume":"5","author":"Hegde SS","year":"2004","journal-title":"Curr Opin Invest Drugs"},{"key":"e_1_2_10_120_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-006-0103-0"},{"key":"e_1_2_10_121_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.067140"},{"key":"e_1_2_10_122_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2004.03.044"},{"key":"e_1_2_10_123_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)89661-6"},{"key":"e_1_2_10_124_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-002-0554-x"},{"key":"e_1_2_10_125_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)00017-0"},{"key":"e_1_2_10_126_2","doi-asserted-by":"publisher","DOI":"10.1254\/fpj.113.157"},{"key":"e_1_2_10_127_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.23.1995"},{"key":"e_1_2_10_128_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64684-8"},{"key":"e_1_2_10_129_2","unstructured":"Oxytrol (Oxybutynin Transdermal System).Full Prescribing Information.Watson Pharmaceuticals Inc. Corona CA USA;2005"},{"key":"e_1_2_10_130_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02201987"},{"key":"e_1_2_10_131_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1532-5415.2001.49144.x"},{"key":"e_1_2_10_132_2","unstructured":"Detrol (Tolterodine tartrate tablets).Full Prescribing Information. Pharmacia & Upjohn Company Kalamazoo MI USA;2003"},{"key":"e_1_2_10_133_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)00483-0"},{"key":"e_1_2_10_134_2","unstructured":"Detrol LA (Tolterodine tartrate extended release capsules).Full Prescribing Information. Pharmacia & Upjohn Company Kalamazoo MI USA;2003"},{"key":"e_1_2_10_135_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.10.061"},{"key":"e_1_2_10_136_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1532-5415.2002.50203.x"},{"key":"e_1_2_10_137_2","first-page":"439","article-title":"Trospium chloride in patients with motor urge syndrome (detrusor instability): a double\u2010blind, randomized, multicentre, placebo\u2010controlled study","volume":"1","author":"Alloussi S","year":"1998","journal-title":"J Clin Res"},{"key":"e_1_2_10_138_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2000.00575.x"},{"key":"e_1_2_10_139_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000127742.73136.0c"},{"key":"e_1_2_10_140_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000140729.07840.16"},{"key":"e_1_2_10_141_2","unstructured":"Enablex\u00ae (Darifenacin).Full Prescribing Information. Novartis Pharmaceuticals Corporation East Hanover NJ USA;2004"},{"key":"e_1_2_10_142_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05343.x"},{"key":"e_1_2_10_143_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1998.00717.x"},{"key":"e_1_2_10_144_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)68810-6"},{"key":"e_1_2_10_145_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(04)90174-9"},{"key":"e_1_2_10_146_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2000.00623.x"},{"key":"e_1_2_10_147_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66095-8"},{"key":"e_1_2_10_148_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001929970003"},{"key":"e_1_2_10_149_2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00345-003-0321-8","article-title":"Controlled, double\u2010blind, multicentre clinical trial to investigate long\u2010term tolerability and efficacy of trospium chloride in patients with detrusor instability","volume":"20","author":"Halaska M","year":"2003","journal-title":"World J Urol"},{"key":"e_1_2_10_150_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2003.04468.x"},{"key":"e_1_2_10_151_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-2042.2002.00460.x"},{"key":"e_1_2_10_152_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66326-4"},{"key":"e_1_2_10_153_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(99)00661-4"},{"key":"e_1_2_10_154_2","doi-asserted-by":"publisher","DOI":"10.4065\/78.6.687"},{"key":"e_1_2_10_155_2","first-page":"243","article-title":"A comparison of extended\u2010release oxybutynin and tolterodine for treatment of overactive bladder in women","volume":"15","author":"Sand PK","year":"2004","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"e_1_2_10_156_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(03)00356-X"},{"key":"e_1_2_10_157_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.04.023"},{"key":"e_1_2_10_158_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.03.016"},{"key":"e_1_2_10_159_2","doi-asserted-by":"publisher","DOI":"10.1159\/000096338"},{"key":"e_1_2_10_160_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2004.04561.x"},{"key":"e_1_2_10_161_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-002-1009-0"},{"key":"e_1_2_10_162_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)01113-4"},{"key":"e_1_2_10_163_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.05.015"},{"key":"e_1_2_10_164_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(98)00585-2"},{"key":"e_1_2_10_165_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427130-00005"},{"key":"e_1_2_10_166_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(97)01554-0"},{"key":"e_1_2_10_167_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04710"},{"key":"e_1_2_10_168_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032426"},{"key":"e_1_2_10_169_2","first-page":"H168","article-title":"Excess tachycardia: heart rate after antimuscarinic agents in conscious dogs","volume":"246","author":"Rigel DF","year":"1984","journal-title":"Am J Physiol"},{"key":"e_1_2_10_170_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1474-8673.1992.tb00384.x"},{"key":"e_1_2_10_171_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1996.tb00161.x"},{"key":"e_1_2_10_172_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200124090-00005"},{"key":"e_1_2_10_173_2","unstructured":"Detrol LA\u00ae (tolterodine tartrate).Full Prescribing Information. Pharmacia & Upjohn Company Kalamazoo MI USA;2005"},{"key":"e_1_2_10_174_2","doi-asserted-by":"publisher","DOI":"10.1159\/000020221"},{"key":"e_1_2_10_175_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000181823.33224.a0"},{"key":"e_1_2_10_176_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2004.05039.x"},{"key":"e_1_2_10_177_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000067541.73285.eb"},{"key":"e_1_2_10_178_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000173630.94559.fd"},{"key":"e_1_2_10_179_2","first-page":"525","article-title":"A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and\/or urinary incontinence","volume":"12","author":"Saitoh H","year":"1999","journal-title":"Jpn J Urol Surg"},{"key":"e_1_2_10_180_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.19.2319"},{"key":"e_1_2_10_181_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.01.006"},{"key":"e_1_2_10_182_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.11-10-03218.1991"},{"key":"e_1_2_10_183_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1998.tb01006.x"},{"key":"e_1_2_10_184_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.02.014"},{"key":"e_1_2_10_185_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-004-0064-0"},{"key":"e_1_2_10_186_2","unstructured":"WesnesK LiptonRB KolodnerK EdgarC.Darifenacin an M3selective receptor antagonist for the treatment of overactive bladder does not affect cognitive function in elderly volunteers.19th Congress of the European Association of Urology; 2004 March 24\u201327; Vienna Austria;2004"},{"key":"e_1_2_10_187_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05296.x"},{"key":"e_1_2_10_188_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.5.771"},{"key":"e_1_2_10_189_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.55.11.1318-a"},{"key":"e_1_2_10_190_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200312043492325"},{"key":"e_1_2_10_191_2","unstructured":"Ditropan\u00ae (oxybutynin chloride).Full Prescribing Information. ALZA Corporation Mountain View CA USA;1998"},{"key":"e_1_2_10_192_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01569-2"},{"key":"e_1_2_10_193_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000157685.83573.79"},{"key":"e_1_2_10_194_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.02.026"},{"key":"e_1_2_10_195_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000085667.05190.ad"},{"key":"e_1_2_10_196_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2003.04085.x"},{"key":"e_1_2_10_197_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05641.x"},{"key":"e_1_2_10_198_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2006.01240.x"},{"key":"e_1_2_10_199_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000152322.17542.63"},{"key":"e_1_2_10_200_2","doi-asserted-by":"crossref","unstructured":"NijmanRJ BorgsteinNG EllsworthP SiggaardC.Long\u2010term tolerability of tolterodine extended release in children 5\u201311 years of age: Results from a 12\u2010Month Open\u2010Label Study.Eur Urol2007: [Epub ahead of print]","DOI":"10.1016\/j.eururo.2007.05.002"},{"key":"e_1_2_10_201_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64115-8"},{"key":"e_1_2_10_202_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2003.10.009"},{"key":"e_1_2_10_203_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0094-0143(05)70298-6"},{"key":"e_1_2_10_204_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.02.046"},{"key":"e_1_2_10_205_2","doi-asserted-by":"publisher","DOI":"10.1080\/07399339309516084"},{"key":"e_1_2_10_206_2","doi-asserted-by":"publisher","DOI":"10.1177\/105477380000900205"},{"key":"e_1_2_10_207_2","unstructured":"AbramsP AnderssonKE BrubakerLet\u2003al.3rd International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence pelvic organ prolapse and faecal incontinence: International Continence Society;2005. Available at:http:\/\/www.icsoffice.org\/documents\/ici_pdfs_3\/v2.pdf\/summary.pdf. Accessed June 2007"},{"key":"e_1_2_10_208_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02850085"},{"key":"e_1_2_10_209_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2003.04351.x"},{"key":"e_1_2_10_210_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032662"},{"key":"e_1_2_10_211_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0277-9536(97)00128-7"},{"key":"e_1_2_10_212_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.41.1.691"},{"key":"e_1_2_10_213_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64261-9"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2007.07205.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2007.07205.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:08:54Z","timestamp":1761746934000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2007.07205.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,3]]},"references-count":212,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["10.1111\/j.1464-410X.2007.07205.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2007.07205.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,3]]},"assertion":[{"value":"2007-10-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}